Table 2.

Impact on healthcare providers: summary results per child receiving adjunctive therapy (15 years)

		England		Ireland		Italy		Spain
	Total QALYs	Total Costs (€; 2020)	ICER (€; 2020)	Total Costs (€; 2020)	ICER (€; 2020)	Total Costs (€; 2020)	ICER (€; 2020)	Total Costs (€; 2020)	ICER (€; 2020)
(Continued monotherapy)$	9.41	23,495	(comparator)	9,647	(comparator)	8,057	(comparator)	10,208	-
Gabapentin	9.46	24,100	12,083^	7,128	Preferred*	5,381	Preferred*	9,599	Dominated
Lamotrigine	9.47	24,290	Dominated	13,694	Dominated	10,692	Dominated	9,944	Dominated
Topiramate	9.51	25,376	Dominated	12,838	Dominated	7,757	Dominated	8,456	Dominated
Levetiracetam	9.52	26,169	Dominated	8,426	Dominated	10,496	Dominated	7,886	Dominated
Oxcarbazepine	9.52	25,218	15,657^	8,806	Dominated	6,084	Dominated	6,721	Preferred*

$ comparator; ^ More cost-effective than comparator; *More effective and cost-saving than comparator

ICER (incremental cost effectiveness ratio) = cost per additional QALY gained